Clinical Trials Sponsored by Cynthia Harris

Total 4834 results

Aeris Therapeutics

Completed

US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

Pulmonary Emphysema

United States
Auris Medical AG

Completed

AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS)

Vestibular Vertigo

France
Auris Medical AG

Completed

AM-101 in the Treatment of Acute Tinnitus 3 (TACTT3)

Tinnitus

Germany
Auris Medical AG

Completed

Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss

Hearing Loss

Germany
AURA Paris

Completed

Immune Response Following COVID-19 in Hemodialysis Patients (IMMUNOVIDIAL)

COVID-19 | Cytokine Storm | Dialysis; Complications

France
Aeris Therapeutics

Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease(COPD)

Israel
Aeris Therapeutics

Terminated

Post Market Registry Study of the AeriSeal System

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Terminated

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Emphysema | Chronic Pulmonary Obstructive Disease

Germany, Israel, Austria, France
Aeris Therapeutics

Completed

AeriSeal System for Lung Volume Reduction

Lung Diseases | Emphysema | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease (COPD)

Israel, Austria, France, Germany
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Advanced Emphysema

Germany
Aeris Therapeutics

Terminated

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Netherlands
Aeris Therapeutics

Terminated

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Israel
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Pulmonary Emphysema

United States
Robin Carhart-Harris, PhD, MA

Recruiting

Neural and Physiological Correlates of Psychedelic Sub-states (i2)

Healthy Volunteers | Psychedelic Experiences | Neuroimaging

United States
Stewart Harris
Juvenile Diabetes Research Foundation

Completed

Healthy Moms, Healthy Babies (HMHB)

Type 2 Diabetes Mellitus | Gestational Diabetes

Canada
First Affiliated Hospital of Harbin Medical University
Harbin Medical University

Withdrawn

Sonodynamic Therapy on Patients With Femoropopliteal PAD and Claudication

Cardiovascular Diseases | Peripheral Arterial Disease | Atherosclerosis
Assistance Publique - Hôpitaux de Paris
ESPCI Paris

Completed

Sublingual Milk Immunotherapy in Children (Lactaide)

Cow Milk Allergy

France
Harbin Medical University
Abbott

Recruiting

OPTical Coherence Tomography IMAging in Patients With Acute myocardiaL Infarction (OPTIMAL) (OPTIMAL)

Acute Myocardial Infarction

China
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

Nicotine | Nicotine Vaping | Vaping

United States
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - London (UK)

Tobacco Use

Switzerland
Philip Morris Products S.A.

Completed

Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS

Smoking | Tobacco Use | Tobacco Smoking

United Kingdom
Philip Morris Products S.A.

Withdrawn

Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease

Cardiovascular Diseases | Coronary Artery Disease | Smoking | Peripheral Arterial Disease | Tobacco Use
Pardis Specialized Wellness Institute

Completed

Inactivity and Quality of Life in Dialysis Patients

Chronic Kidney Diseases | Peritoneal Dialysis | End Stage Renal Disease | Hemodialysis Complication

Iran, Islamic Republic of
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.

Smoking

Poland
Philip Morris Products S.A.

Completed

Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome

Periodontal Diseases | Gingival Diseases | Chronic Periodontitis | Smoking, Cigarette | Periodontal Pocket | Tooth Mobility

Japan
Philip Morris Products S.A.

Completed

Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

Smoking

United States
Pardis Specialized Wellness Institute

Completed

The Effect of Exercise on Blood Parameters Related to Dialysis Patients' Survival

Chronic Kidney Diseases | Hemodialysis | End Stage Renal Disease

Iran, Islamic Republic of
Philip Morris Products S.A.

Completed

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

Smoking

United States
Philip Morris Products S.A.

Completed

Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure

Smokers | Never Smokers

United States
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Smoking

United Kingdom
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L

Smoking

New Zealand
Philip Morris Products S.A.

Completed

Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers

Smoking | Healthy

Japan
Philip Morris Products S.A.

Completed

Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article

Smoking

Poland
Philip Morris Products S.A.

Completed

Real-Life Passive Exposure Assessment of IQOS

Environmental Exposure

Japan
Harrison International Peace Hospital

Completed

Efficacy and Safety of Cemented and Cementless Prostheses for Unstable Intertrochanteric Fractures in the Elderly

Intertrochanteric Fractures
Philip Morris Products S.A.

Completed

Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study

COPD

United Kingdom
Rafic Hariri University Hospital

Unknown

Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study

Retinitis Pigmentosa | Cystoid Macular Edema
Ankara University
Harran University

Completed

Ultrasonography of the Neck: The Influence of Airway Devices on Vascular Topography in Pediatric Patients

Ultrasonography, Pediatrics, Overlap, Vascular Structures

Turkey
Rafic Hariri University Hospital

Unknown

Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I (ZIV)

Central Retinal Vein Occlusion | Age Related Macular Degeneration

Lebanon
Philip Morris Products S.A.

Recruiting

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Smoking | Tobacco Use | COPD

United States, Bulgaria, Czechia, Germany, Japan, Romania, Slovakia, United Kingdom
Philip Morris Products S.A.

Completed

Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking

Smoking | Inflammation | Oxidative Stress | Smoking Abstinence

Japan, Germany, Czechia, Greece
Philip Morris Products S.A.

Completed

Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence

Nicotine | Nicotine Vaping | Vaping

United Kingdom
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - Italy

Tobacco Use

Switzerland
Philip Morris Products S.A.

Active, not recruiting

Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)

Tobacco Use

Canada
Pardis Specialized Wellness Institute

Completed

Validity of Low Physical Activity Questionnaire (LoPAQ)

Chronic Kidney Diseases | End Stage Renal Disease | Hemodialysis Complication

Iran, Islamic Republic of
Philip Morris Products S.A.

Completed

Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.

Smoking | Abdominal Aortic Aneurysm | IQOS Use

Japan
Philip Morris Products S.A.

Completed

A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation (RIBESC)

Cigarette Smoking

United States, Poland, Germany, Japan, United Kingdom
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers

Smoking | Nicotine

United Kingdom
Philip Morris Products S.A.

Completed

Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it

Pharmacokinetics

Russian Federation

Clinical Trials Sponsored by Cynthia Harris

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations